This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Timmer-Bonte JNH, Adang EMM, Smit HJM, Biesma B, Wilschut FA, Bootsma GP, de Boo TM, Tjan-Heijnen VCG.Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. Journal of Clinical Oncology 24: 2991-2997, No. 19, 1 Jul 2006
Adams JR, Angelotta C, Bennett CL.When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective? Journal of Clinical Oncology 24: 2975-2977, No. 19, 1 Jul 2006
Rights and permissions
About this article
Cite this article
G-CSF worth extra cost to prevent febrile neutropenia?. Pharmacoecon. Outcomes News 508, 3 (2006). https://doi.org/10.2165/00151234-200605080-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200605080-00006